- Home
- LFWD vs IMNN Comparison
LFWD vs IMNN Comparison
Compare LFWD & IMNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LFWD
- IMNN
- Stock Information
- Founded
- LFWD 2001
- IMNN 1982
- Country
- LFWD Israel
- IMNN United States
- Employees
- LFWD N/A
- IMNN N/A
- Industry
- LFWD
- IMNN Biotechnology: Pharmaceutical Preparations
- Sector
- LFWD
- IMNN Health Care
- Exchange
- LFWD NYSE
- IMNN Nasdaq
- Market Cap
- LFWD 10.5M
- IMNN 12.1M
- IPO Year
- LFWD 2014
- IMNN 1985
- Fundamental
- Price
- LFWD $0.78
- IMNN $7.00
- Analyst Decision
- LFWD Strong Buy
- IMNN Buy
- Analyst Count
- LFWD 3
- IMNN 2
- Target Price
- LFWD $9.00
- IMNN $14.00
- AVG Volume (30 Days)
- LFWD 804.6K
- IMNN 4.1M
- Earning Date
- LFWD 08-14-2025
- IMNN 08-13-2025
- Dividend Yield
- LFWD N/A
- IMNN N/A
- EPS Growth
- LFWD N/A
- IMNN N/A
- EPS
- LFWD N/A
- IMNN N/A
- Revenue
- LFWD $25,414,000.00
- IMNN N/A
- Revenue This Year
- LFWD $12.04
- IMNN N/A
- Revenue Next Year
- LFWD $40.58
- IMNN N/A
- P/E Ratio
- LFWD N/A
- IMNN N/A
- Revenue Growth
- LFWD 41.92
- IMNN N/A
- 52 Week Low
- LFWD $0.50
- IMNN $0.37
- 52 Week High
- LFWD $4.77
- IMNN $7.66
- Technical
- Relative Strength Index (RSI)
- LFWD 43.98
- IMNN 35.49
- Support Level
- LFWD $0.70
- IMNN $7.46
- Resistance Level
- LFWD $0.84
- IMNN $9.35
- Average True Range (ATR)
- LFWD 0.07
- IMNN 1.23
- MACD
- LFWD 0.03
- IMNN 0.08
- Stochastic Oscillator
- LFWD 44.88
- IMNN 9.00
About LFWD REWALK ROBOTICS LTD
Lifeward Ltd is a medical device company that designs, develops, and commercializes life-changing solutions that span the continuum of care in physical rehabilitation and recovery, delivering functional and health benefits in clinical settings as well as in the home and community. Its product offerings are the ReWalk Exoskeleton, the ReStore Exo-Suit, the MyoCycle FES bikes, and AlterG Anti-Gravity systems. It operates through markets in the United States, Israel, and Germany.
About IMNN Imunon Inc.
Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across various human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. Its clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer that has completed Phase II clinical studies. Additionally, the Company has entered a first-in-human study of its COVID-19 booster vaccine (IMNN-101).